滤泡性淋巴瘤的预后分层和治疗进展

doi:10.11904/j.issn.1002-3070.2020.02.019

摘要/Abstract

摘要： 滤泡性淋巴瘤(Follicular lymphoma,FL)是非霍奇金淋巴瘤(Non-Hodgkin's lymphoma,NHL)中发病率仅次于弥漫大B细胞淋巴瘤的常见B细胞淋巴瘤。FL属于惰性淋巴瘤,尽管该疾病进展缓慢但并不能治愈,且由于复发及进展,严重影响着患者的生存。近年来,针对FL的“无化疗”方案疗效确切且毒性较低,新型免疫治疗和靶向药物也显示较好疗效,受到研究者的广泛关注。为进一步加深临床医生对FL治疗新进展的认识,本文对FL的分层及治疗进展进行综述。

关键词: 滤泡性淋巴瘤, 治疗, 预后, 免疫

Abstract: Follicular lymphoma(FL)is a common B-cell lymphoma with an incidence of non-Hodgkin's lymphoma(NHL)that is second only to diffuse large B lymphoma.FL is an indolent lymphoma.Although the disease progresses slowly,it cannot be cured,and due to recurrence and progression,it seriously affects the survival of patients.In recent years,the“no-chemotherapy”regimen for FL has exact curative effect and low toxicity;the new immunotherapy and targeted drugs also show good curative effect,which has attracted widespread attention from researchers.In order to further deepen the clinician's understanding of the new progress of FL treatment,this article reviews the stratification and treatment progress of FL.

Key words: Follicular lymphoma, Treatment, Prognosis, Immunity

中图分类号:

R733.4

苏文佳, 王树叶. 滤泡性淋巴瘤的预后分层和治疗进展[J]. 实用肿瘤学杂志, 2020, 34(2): 189-192.

SU Wenjia, WANG Shuye. Prognostic stratification and treatment progress of follicular lymphoma[J]. Journal of Practical Oncology, 2020, 34(2): 189-192.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.02.019

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I2/189

参考文献

1 Lossos IS,Gascoyne RD.Transformation of follicular lymphoma[J].Best Pract Res Clin Haematol,2011,24(2):147-163.
2 Vyas P.Pathology and genetics:tumours of haematopoietic and lymphoid tissues[J].Lancet Oncol,2001,2(1):770.
3 中华医学会血液学分会,中国抗癌协会淋巴瘤专业委员会.中国滤泡性淋巴瘤诊断与治疗指南(2013年版)[J].中华血液学杂志,2013,34(9):820-824.
4 Rivas-Delgado A,Magnano L,Moreno-Velázquez M,et al.Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era[J].Br J Haematol,2019,184(5):753-759.
5 Tobin JWD,Keane C,Gunawardana J,et al.Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration[J].Clin Oncol,2019,37(34):3300-3309.
6 Freedman A.Follicular lymphoma:2018 update on diagnosis and management[J].Am J Hematol,2018,93(2):296-305.
7 YavaşS,Ayaz S,Köse SK,et al.Influence of blood collection systems on coagulation tests[J].Turk J Haematol,2012,29(4):367-375.
8 Pina-Oviedo S,Wang W,Vicknair E,et al.Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells[J].Pathology,2017,49(5):544.
9 Solal-Celigny P.Follicular lymphoma international prognostic index[J].Curr Treat Options Oncol,2006,7(4):270-275.
10 Federico M,Luminari S,Iannitto E,et al.ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma:results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial[J].J Clin Oncol,2009,27(5):805-811.
11 Pastore A,Jurinovic V,Kridel R,et al.Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma:a retrospective analysis of a prospective clinical trial and validation in a population-based registry[J].Lancet Oncol,2015,16(9):1111-1122.
12 Gallamini A,Borra A.FDG-PET Scan:a new paradigm for follicular lymphoma management[J].Mediterr J Hematol Infect Dis,2017,9(1):e2017029.
13 Meignan M,Cottereau AS,Versari A,et al.Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma:a pooled analysis of three multicenter studies[J].J Clin Oncol,2016,34(30):3618-3626.
14 Bachy E,Maurer MJ,Habermann TM,et al.A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy[J].Blood,2018,132(1):49-58.
15 Marc S,Laia LV,Juan-Manuel S.Predictive gene-expression score for follicular lymphoma[J].Lancet Oncol,2018,19(6):e279.
16 Qu X,Li H,Braziel RM,et al.Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016[J].Blood,2019,133(1):81-93.
17 Jurinovic V,Kridel R,Staiger AM,et al.Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy[J].Blood,2016,128(8):1112.
18 Pott C,Hoster E,Kehden B,et al.Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study[J].Blood,2016,128:613.
19 Luminari S,Biasoli I,Versari A,et al.The prognostic role of post-induction FDG-PET in patients with follicular lymphoma:a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi(FIL)[J].Ann Oncol,2014,25(2):442-447.
20 Luminari S,Galimberti S,Versari A,et al.Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma.A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi[J].Haematologica,2016,101(2):66-68.
21 Fowler NH,Davis RE,Rawal S,et al.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma:an open-label,phase 2 trial[J].Lancet Oncol,2014,15(12):1311-1318.
22 Gribben JG,Fowler N,Morschhauser F.Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma[J].J Clin Oncol,2015,33(25):2803-2811.
23 Younes A,Brody J,Carpio C,et al.Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia:a phase 1/2a study[J].Lancet Haematol,2019,6(2):67-78.
24 Advani R,Flinn I,Popplewell L,et al.CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin's lymphoma[J].N Engl J Med,2018,379(18):1711-1721.

[1]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[2]	朱玉成, 孙昕, 孟丹. 酮咯酸氨丁三醇预防性镇痛对肺癌手术患者免疫功能的影响[J]. 实用肿瘤学杂志, 2020, 34(2): 176-180.
[3]	廖代祥, 郑博, 张彦斌, 于军辉. RRBP1与RABEX-5蛋白在结直肠癌组织中的表达及与临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2020, 34(1): 43-48.
[4]	李国政, 庞达. HER2阳性乳腺癌治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 74-78.
[5]	张景岚, 刘瑞宝. 结直肠癌肝转移瘤局部介入治疗应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 79-82.
[6]	左志博, 郭志琴, 王振, 杨宏杰, 邬万新. Semaphorin 3F在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 88-92.
[7]	刘耿淳, 申良方. 血清长链非编码RNA MALAT1和AFAP1-AS1与鼻咽癌临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2019, 33(6): 513-518.
[8]	曹舒, 李莎莎, 杨丹. 信号通路相关的microRNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 544-548.
[9]	曹涤非, 黄国庆, 薛佳莹, 吴琼, 王雷, 李瑶. CA153在乳腺癌免疫治疗中的作用[J]. 实用肿瘤学杂志, 2019, 33(6): 566-569.
[10]	张玉海, 李月敏. 人工智能在肿瘤放射治疗中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 570-574.
[11]	沈依哲, 郭宝良. 初诊Ⅳ期乳腺癌的局部治疗研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 575-578.
[12]	范晋海, 蒋玉梅, 张静, 白晓静. MAP1A在膀胱癌组织中的表达及其与临床病理特征的关系[J]. 实用肿瘤学杂志, 2019, 33(6): 525-530.
[13]	李素素, 周春祥. NKT细胞对肝癌免疫应答的双向调控作用[J]. 实用肿瘤学杂志, 2019, 33(6): 540-543.
[14]	刘四卫, 崔玥, 孙元元, 胡晶, 张文睿, 曹孟儒. FOXD3在肺癌细胞中的作用[J]. 实用肿瘤学杂志, 2019, 33(5): 390-396.
[15]	夏天一, 张博淼, 姚克非, 崔滨滨. PTPN9表达水平与结直肠癌的临床关系研究[J]. 实用肿瘤学杂志, 2019, 33(5): 415-419.